Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05080673 · ClinicalTrials.gov registry record · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
A NA study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon, sponsored by NRG Oncology.
- Recruiting
- Registry status
- NA
- Development phase
- 9,500
- Enrollment target
- 20
- Study locations
NCT05080673 is a NA study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 9,500 participants, above the 48-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (19692% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05080673, a NA study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- NA
- Development phase
- 9,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Conditions Studied
Interventions
- PROCEDURE 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- PCR Oncology - Arroyo Grande
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
- Epic Care-Dublin - Dublin
- Mercy Cancer Center - Elk Grove - Elk Grove
- Bay Area Breast Surgeons Inc - Emeryville
- Epic Care Partners in Cancer Care - Emeryville
- Kaiser Permanente-Fontana - Fontana
Arizona
- CTCA at Western Regional Medical Center - Goodyear
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- University of Arizona Cancer Center - Prevention Research Clinic - Tucson
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- CARTI Cancer Center - Little Rock
Alaska
- Fairbanks Memorial Hospital - Fairbanks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,500 participants |
| Start Date | 2022-02-09 |
| Est. Completion | 2065-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05080673
The ClinicalTrials.gov registry entry for NCT05080673 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 9,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 48-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (19692% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adenocarcinoma of the Rectum appearing as the primary indexed condition, and to 1 intervention - of which 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy is the first listed.
NCT05080673 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05080673 about?
NCT05080673 is a clinical study titled "Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps". This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
What is the current status of trial NCT05080673?
This trial is currently recruiting. It is a NA study. The enrollment target is 9,500 participants. The study started on 2022-02-09. Estimated completion is 2065-11-01.
What conditions does trial NCT05080673 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Rectum, Adenocarcinoma of the Colon.
What interventions are being tested in trial NCT05080673?
The interventions under investigation include: 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT05080673?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05080673 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Rectum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
RECRUITING · NA
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
RECRUITING · Phase 2
-
The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
RECRUITING
-
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
COMPLETED · Phase 2
-
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.